The notices it replaced
- Reissues: PA-10-205 Alzheimers Disease Drug Development Program (U01)
- 2 steps back: PAR-08-266 Alzheimers Disease Drug Development Program (U01)
- 3 steps back: PAR-05-148
Replaced by PAR-15-174.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,998,364 in first-year total cost, median $1,194,177.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-6 (M1)]3
- Special Emphasis Panel[ZAG1 ZIJ-6 (J4)]2
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN DIEGO2
- INSTITUTE FOR MOLECULAR MEDICINE1
- UNIVERSITY OF KENTUCKY1
- UNIVERSITY OF SOUTHERN CALIFORNIA1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2016 | Optimization and preclinical development of soluble gamma-secretase modulators for AD1U01AG048986-01A1 | WAGNER, STEVEN LEE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,514,460 | ZAG1 |
| 2015 | Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD1U01AG050636-01 | VAN ELDIK, LINDA JWATTERSON, DANIEL MARTIN | UNIVERSITY OF KENTUCKY, KY | $1,416,252 | ZAG1 |
| 2015 | Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND1U01AG048310-01A1 | AGADJANYAN, MICHAEL G | INSTITUTE FOR MOLECULAR MEDICINE, CA | $1,152,198 | ZAG1 |
| 2014 | A Translational Program of BDNF Gene Delivery in Alzheimer's Disease1U01AG043416-01A1 | TUSZYNSKI, MARK H. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $1,194,177 | ZAG1 |
| 2014 | Allopregnanolone a Regenerative Therapy for Alzheimer's: FDA-Required Toxicolog1U01AG047222-01 | BRINTON, ROBERTA EILEEN | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $721,277 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.